{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:44:09Z","timestamp":1765820649775,"version":"3.48.0"},"reference-count":19,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R15AI28714-01"],"award-info":[{"award-number":["R15AI28714-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,11,8]]},"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Among men who have sex with men, pre-exposure prophylaxis (PrEP) reduces the risk of HIV by 95%. Based on the documented benefits, the Centre for Disease Control and Prevention has recommended PrEP as a prevention method for high-risk groups. Moreover, for those HIV-infected individuals, antiretroviral therapy has been shown to serve as both as a treatment and prevention method for HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This systematic review protocol was reported according to the Preferred Reporting Items for Systematic reviews and Analyses (PRISMA) P framework. Medline (1980\u2013present), Embase (1980\u2013present), CINAHL (1980\u2013present), Cochrane Central Register of Controlled Trials and clinicaltrials.gov will be used to identify relevant articles based on a piloted search strategy. Peer-reviewed observational and experimental studies will be included. A narrative style will be used to describe descriptive data. A meta-analysis will be conducted if heterogeneity is not significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Recent evidence suggests that there is an increased risk of sexually transmitted infections (STIs) among high-risk persons that use PrEP. Furthermore, there is a paucity of data on the relationship of treatment as prevention and incidence of STIs. The findings of this review will assess this emerging public health phenomenon and serve to inform future public health policy. No formal ethical review is required for this protocol. All findings will be published in a peer reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROTOCOL registration number<\/jats:title>\n                    <jats:p>CRD42019128720.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-032054","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T05:00:13Z","timestamp":1575608413000},"page":"e032054","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Sexually transmitted infections among high-risk populations that use treatment as prevention or pre-exposure prophylaxis: a protocol for a systematic review"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5906-3220","authenticated-orcid":false,"given":"Makella","family":"Coudray","sequence":"first","affiliation":[{"name":"Epidemiology, Florida International University, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Kiplagat","sequence":"additional","affiliation":[{"name":"Epidemiology, Florida International University, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin","family":"Saumell","sequence":"additional","affiliation":[{"name":"Epidemiology, Florida International University, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purnima","family":"Madhivanan","sequence":"additional","affiliation":[{"name":"Health Promotion Sciences, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, United States"},{"name":"Internal Medicine, Division of Infectious Diseases, College of Medicine, University of Arizona, Tucson, Arizona, United States"},{"name":"Family & Community Medicine, College of Medicine, University of Arizona, Tucson, Arizona, United States"},{"name":"Public Health Research Institute of India, Mysore, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"2025121509420219000_9.12.e032054.1","unstructured":"UNAIDS . 2017 global HIV statistics, 2018. Available: http:\/\/www.unaids.org\/en\/resources\/fact-sheet [Accessed 02 Apr 2019]."},{"key":"2025121509420219000_9.12.e032054.2","doi-asserted-by":"crossref","unstructured":"Desai M , Field N , Grant R , et al . Recent advances in pre-exposure prophylaxis for HIV. BMJ 2017;359.doi:10.1136\/bmj.j5011","DOI":"10.1136\/bmj.j5011"},{"key":"2025121509420219000_9.12.e032054.3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/OLQ.0000000000000514","article-title":"Implementation of preexposure prophylaxis for human immunodeficiency virus prevention among men who have sex with men at a new England sexually transmitted diseases clinic","volume":"43","author":"Chan","year":"2016","journal-title":"Sex Transm Dis"},{"key":"2025121509420219000_9.12.e032054.4","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0505-6"},{"key":"2025121509420219000_9.12.e032054.5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","author":"De Clercq","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"2025121509420219000_9.12.e032054.6","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/cid\/cix439","article-title":"Incidence of gonorrhea and Chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study","volume":"65","author":"Jenness","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025121509420219000_9.12.e032054.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.828"},{"key":"2025121509420219000_9.12.e032054.8","doi-asserted-by":"crossref","unstructured":"Anglemyer A , Rutherford GW , Horvath T , et al . Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2013;4.","DOI":"10.1002\/14651858.CD009153.pub3"},{"key":"2025121509420219000_9.12.e032054.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105243"},{"key":"2025121509420219000_9.12.e032054.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091513","article-title":"Daily oral emtricitabine\/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men","volume":"9","author":"Marcus","year":"2014","journal-title":"PLoS One"},{"key":"2025121509420219000_9.12.e032054.11","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2471"},{"key":"2025121509420219000_9.12.e032054.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025121509420219000_9.12.e032054.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2025121509420219000_9.12.e032054.14","unstructured":"Division of HIV\/AIDS Prevention NCfHA, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. Preventing New HIV Infections . Hiv guidelines web site, 2018. Available: https:\/\/www.cdc.gov\/hiv\/guidelines\/preventing.html [Accessed 02 Apr 2019]."},{"key":"2025121509420219000_9.12.e032054.15","unstructured":"FDA . Truvada fact sheet. US department of health and human services web site 2012, 2019."},{"key":"2025121509420219000_9.12.e032054.16","unstructured":"Covidence systematic review software. Available: www.covidence.org"},{"key":"2025121509420219000_9.12.e032054.17","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025121509420219000_9.12.e032054.18","doi-asserted-by":"publisher","DOI":"10.3310\/hta7050"},{"key":"2025121509420219000_9.12.e032054.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-032054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:42:11Z","timestamp":1765820531000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-032054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,5]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1136\/bmjopen-2019-032054"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-032054","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}